From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
Trade names Patanol and others
AHFS/Drugs.com Monograph
MedlinePlus a602025
License data
  • EU EMAby INN
  • C
Routes of
Ophthalmic, intranasal, oral
ATC code
Pharmacokinetic data
Elimination half-life 3 hours
CAS Number
  • 113806-05-6 ☑Y
PubChem CID
  • 5281071
  • DB00768 ☑Y
  • 4444528 ☑Y
  • D27V6190PM
  • D08293 ☑Y
  • CHEMBL1189432 ☒N
ECHA InfoCard 100.133.834
Chemical and physical data
Formula C21H23NO3
Molar mass 337.412 g/mol
3D model (JSmol)
  • Interactive image
 ☒N☑Y (what is this?)   (verify)

Olopatadine is an antihistamine (as well as anticholinergic and mast cell stabilizer), sold as a prescription eye drop manufactured by Alcon in one of three strengths: 0.7% solution or Pazeo in the United States, 0.2% solution or Pataday (also called Patanol S in some countries), and 0.1% or Patanol (also called Opatanol in some countries; Olopat in India). It is used to treat itching associated with allergic conjunctivitis (eye allergies).[1] A steroid-free[2] nasal spray formulation is sold as Patanase, which was approved by the FDA on April 15, 2008.[3] It is also available as an oral tablet in Japan under the tradename Allelock, manufactured by Kyowa Hakko Kogyo.[4]

The usual dose for Patanol is 1 drop in each affected eye 2 times per day, with 6 to 8 hours between doses. Both Pazeo and Pataday are dosed 1 drop in each eye daily.

There is potential for olopatadine as a treatment modality for steroid rebound (red skin syndrome).[5]

Olopatadine was developed by Kyowa Hakko Kogyo.[6]

Side Effects

Some known side effects include headache (7% of occurrence), eye burning and/or stinging (5%), blurred vision, dry eyes, foreign body sensation, hyperemia, keratitis, eyelid edema, pruritus, asthenia, sore throat (pharyngitis), rhinitis, sinusitis, taste perversion, and vomiting.



Olopatadine synthesis:[7]



Olopatadine acts as a selective antagonist of the histamine H1 receptor, thus stabilizing mast cells and inhibiting histamine release.


  1. ^ Castillo M, Scott NW, Mustafa MZ, Mustafa MS, Azuara-Blanco A (2015). "Topical antihistamines and mast cell stabilisers for treating seasonal and perennial allergic conjunctivitis". Cochrane Database Syst Rev. 6 (6): CD009566. doi:10.1002/14651858.CD009566.pub2. PMID 26028608.
  2. ^ How PATANASE® Nasal Spray Works
  3. ^ Drugs.com, Alcon's Patanase Nasal Spray Approved by FDA for Treatment of Nasal Allergy Symptoms
  4. ^ Kyowa Hakko Kogyo Co., Ltd. (2007). "ALLELOCK Tablets 2.5 & ALLELOCK Tablets 5 (English)" (PDF). Retrieved 2008-08-10.
  5. ^ Tamura T; Matsubara M; Hasegawa K; Ohmori K; Karasawa A. (2005). "Olopatadine hydrochloride suppresses the rebound phenomenon after discontinuation of treatment with a topical steroid in mice with chronic contact hypersensitivity". Clin Exp Allergy. 35 (1): 97–103. doi:10.1111/j.1365-2222.2005.02147.x. PMID 15649273.
  6. ^ Kyowa Hakko Kogyo Co., Ltd. (2002). "Company History". Company Information. Kyowa Hakko Kogyo Co., Ltd. Retrieved 16 September 2010.
  7. ^ Ueno, K.; Kubo, S.; Tagawa, H.; Yoshioka, T.; Tsukada, W.; Tsubokawa, M.; Kojima, H.; Kasahara, A. (1976). "6,11-Dihydro-11-oxodibenz[b,e]oxepinacetic acids with potent antiinflammatory activity". Journal of Medicinal Chemistry. 19 (7): 941–946. doi:10.1021/jm00229a017.

External links

  • Pataday website
  • Patanase website
  • Olopatadine Ophthalmic via MedlinePlus
Retrieved from "https://en.wikipedia.org/w/index.php?title=Olopatadine&oldid=856521511"
This content was retrieved from Wikipedia : http://en.wikipedia.org/wiki/Olopatadine
This page is based on the copyrighted Wikipedia article "Olopatadine"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA